Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs.

Cancers (Basel) · 2021 · PMC7918463 · PMID 33668625

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Conversely, PBMCs from all 7 tested canine lymphoma patients showed highly significant response to atezolizumab ( Figure 4 C), whereas avelumab was again ineffective ( Figure 4 D).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.